BioPharmSignal logoBioPharmSignal

Biotech News

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Black Diamond Therapeutics (BDTX)Black Diamond TherapeuticsConference / presentation

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class

Related news

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

BDTXBlack Diamond Therapeutics2026-08-05 20:01 EST

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

View all latest news

Black Diamond Therapeutics

Mutation-Family Precision Oncology Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule. Silevertinib Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to...

Recent company news

BDTXBlack Diamond Therapeutics2026-09-02 20:01 EST

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

BDTXBlack Diamond Therapeutics2026-08-05 20:01 EST

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-05-22 12:00 EST

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

BDTXBlack Diamond Therapeutics2026-05-21 21:14 EST

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

BDTXBlack Diamond Therapeutics2026-05-19 12:00 EST

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Stock data

Close
1.89 USD
Market cap
124.92M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States